Corbus Pharmaceuticals Holdings annual ebitda margin
2015
2016
2017
2018
2019
2020
2021
Corbus Pharmaceuticals Holdings EBITDA Margin Growth & History (CRBP)
Corbus Pharmaceuticals Holdings's ebitda margin was −6,236.69% for fiscal 2021.
View full Corbus Pharmaceuticals Holdings company overviewCorbus Pharmaceuticals Holdings annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2021 | 2021-12-31 | −6,236.69% | −3146.03 pp |
| 2020 | 2020-12-31 | −3,090.66% | −2879.38 pp |
| 2019 | 2019-12-31 | −211.28% | +955.26 pp |
| 2018 | 2018-12-31 | −1,166.54% | +157.42 pp |
| 2017 | 2017-12-31 | −1,323.96% | −282.99 pp |
| 2016 | 2016-12-31 | −1,040.97% | +317.76 pp |
| 2015 | 2015-12-31 | −1,358.73% | — |
Corbus Pharmaceuticals Holdings quarterly ebitda margin
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q3 2021 | 2021-09-30 | −13,993.73% | −11249.44 pp |
| Q2 2021 | 2021-06-30 | −12,036.94% | +1170.34 pp |
| Q1 2021 | 2021-03-31 | −2,337.36% | −659.45 pp |
| Q4 2020 | 2020-12-31 | −3,119.13% | −2073.20 pp |
| Q3 2020 | 2020-09-30 | −2,744.29% | −1781.32 pp |
| Q2 2020 | 2020-06-30 | −13,207.28% | −13213.67 pp |
| Q1 2020 | 2020-03-31 | −1,677.91% | −279.47 pp |
| Q4 2019 | 2019-12-31 | −1,045.92% | −141.26 pp |
| Q3 2019 | 2019-09-30 | −962.97% | +390.58 pp |
| Q2 2019 | 2019-06-30 | 6.40% | +1443.68 pp |
| Q1 2019 | 2019-03-31 | −1,398.44% | −158.70 pp |
| Q4 2018 | 2018-12-31 | −904.67% | — |
| Q3 2018 | 2018-09-30 | −1,353.56% | −495.83 pp |
| Q2 2018 | 2018-06-30 | −1,437.29% | +635.50 pp |
| Q1 2018 | 2018-03-31 | −1,239.74% | −666.11 pp |
| Q3 2017 | 2017-09-30 | −857.72% | −142.18 pp |
| Q2 2017 | 2017-06-30 | −2,072.78% | −1020.92 pp |
| Q1 2017 | 2017-03-31 | −573.63% | +150.01 pp |
| Q4 2016 | 2016-12-31 | −2,007.74% | −1326.13 pp |
| Q3 2016 | 2016-09-30 | −715.54% | +598.73 pp |
| Q2 2016 | 2016-06-30 | −1,051.87% | +1197.93 pp |
| Q1 2016 | 2016-03-31 | −723.64% | — |
| Q4 2015 | 2015-12-31 | −681.60% | — |
| Q3 2015 | 2015-09-30 | −1,314.27% | — |
| Q2 2015 | 2015-06-30 | −2,249.79% | — |
Corbus Pharmaceuticals Holdings ebitda margin trends
Over the last five fiscal years, Corbus Pharmaceuticals Holdings's ebitda margin decreased from −1,040.97% to −6,236.69%, a change of −5195.72 percentage points. The latest reported quarter, Q3 2021, shows −13,993.73%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Corbus Pharmaceuticals Holdings source filings ↗